Akebia Therapeutics (Akebia Therapeutics) Risk Assessment

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Akebia Therapeutics is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Akebia Therapeutics's Risk Assessment

For the Biotechnology subindustry, Akebia Therapeutics's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics's Risk Assessment Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Risk Assessment falls into.

Akebia Therapeutics (NAS:AKBA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Akebia Therapeutics Risk Assessment Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (Akebia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

AX9:Germany AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Executives

Ellen Snow	officer: SVP, CFO and Treasurer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan	officer: SVP, Chief Business Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas	officer: SVP, General Counsel, Sec.	20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman	officer: SVP, CFO and Treasurer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke	officer: SVP, Chief Medical Officer	82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler	director, officer: CEO & President	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau	officer: SVP, Chief Accounting Officer	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson	director	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham	officer: CCO	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt	director	C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen	director
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy	officer: SVP, Chief Development Officer	ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142